ClinTec International has announced the appointment of Dr Nuggehally Srinivas to join its global operations as Executive Vice President – Asia, from its Indian office in Bangalore. As part of the next phase of an expansion and investment programme in India, Dr Srinivas plays a pivotal leadership role within the Indian operations and as the overall head for ClinTec in Asia.

Dr Srinivas who has been trained as a clinical pharmacologist in the USA, has over seventeen years of drug development experience in the Pharmaceutical industry. He held positions of increasing responsibility at Bristol-Myers Squibb (BMS, Princeton, NJ) in his tenure of over a decade in the USA. At BMS, Dr Srinivas worked on a range of NCEs across wide therapeutic areas leading to pre-clinical, clinical development and NDA filings. Recently, he held the title of Executive Vice President, Drug Development at Dr.Reddy's Laboratories (DRL), Hyderabad, India. In DRL, Dr Srinivas led, formed strategy for, and operationalized drug development initiatives including seamless integration of pre- clinical and clinical functions. Dr Srinivas holds editorial board position in several international journals and has published over 120 research articles. To the ClinTec group, Dr Srinivas brings a solid track record in pre-clinical and clinical drug development activities.

The recruitment of Dr Srinivas is further evidence of ClinTec’s push to provide ongoing guidance, support and international partnering opportunity to the Pharmaceutical industry within India, in the mission to globalize the output from Indian drug discovery and research.

Commenting on the appointment, Dr Rabinder Buttar, President and Founder, ClinTec International, said “the induction of Dr Srinivas to ClinTec at an executive level would help the company execute the next phase of the expansion plan in India. The hire signals our intent to further build our regional capability to global standards using the best talent the industry has to offer, and India plays a key part of our global strategy”.

Bobby Bal, Senior Director at ClinTec International said, “ClinTec is committed to adding strength in depth in strategic markets for clinical research. We are confident that in Dr Srinivas we have the leadership skills which will further push our staff in India to build on their current significant achievements, and reach the next level of clinical excellence through mentoring. Dr Srinivas brings the domain expertise and international outlook to set ClinTec apart in India from the local competition, and offers our international clients a strong leader in India who has experience of working across cultures and geographical boundaries. We are in a global business and this is reflected in the approach of all our staff”.

- End -

About ClinTec International:

ClinTec International is a privately owned full service global clinical research organization, which was founded in 1997 by Dr Rabinder Buttar, the company’s President & CEO. ClinTec International is headquartered in Windsor, UK and has a presence in more than 30 countries covering Western Europe, Central & Eastern Europe, Middle East and Gulf States, North and South Africa, India and the US. In addition to ClinTec’s vast expertise in oncology, it has also conducted over a 150 clinical trials in many other therapeutic areas including anti-infectives, cardiology, dermatology, gastroenterology, neurology, respiratory medicine and rheumatology. ClinTec International excels in conducting clinical studies in diverse geographical locations, supported by a team of world class project managers and clinical research associates. ClinTec International’s ‘fast, flexible and focused’ approach to clinical research ensures an added advantage to the drug development process.